Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease

Venneri, A and McGeown, WJ and Shanks, MF (2005) Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. NeuroReport, 16 (2). pp. 107-110. ISSN 0959-4965

Full text not available in this repository.Request a copy from the Strathclyde author

Abstract

Brain grey matter density changes were quantified using voxel based morphometry in 26 patients with minimal to mild Alzheimer's disease (AD) treated with three cholinesterase inhibitors over 20 weeks. Patients whose drug treatment also inhibited butyrylcholinesterase did not show the widespread cortical atrophic changes in parietotemporal regions invariably reported in untreated AD patients, and which were detectable in the subgroups treated with selective acetylcholinesterase inhibition. This finding is the first empirical evidence that dual cholinesterase inhibition may have neuroprotective potential in AD. (C) 2005 Lippincott Williams Wilkins.

Creators(s):	Venneri, A, McGeown, WJ ORCID: https://orcid.org/0000-0001-7943-5901 and Shanks, MF;
Item type:	Article
ID code:	44496
Keywords:	treatment, Alzheimer's disease, dementia, cholinesterase inhibitors, disease progression, donepezil, neuroimaging, grey matter, rivastigmine, galantamine, MRI, Neuroscience. Biological psychiatry. Neuropsychiatry, Neuropsychology and Physiological Psychology
Subjects:	Medicine > Internal medicine > Neuroscience. Biological psychiatry. Neuropsychiatry
Department:	Faculty of Humanities and Social Sciences (HaSS) > School of Psychological Science and Health > Psychology
Depositing user:	Pure Administrator
Date deposited:	12 Aug 2013 14:34
Last modified:	01 Jan 2021 10:41
Related URLs:	Journal or Publication
URI:	https://strathprints.strath.ac.uk/id/eprint/44496
Export data:

CORE (COnnecting REpositories)